SCHEDULE: Cooperman Discloses 6.3% Stake in DiaMedica Therapeutics

Leon G. Cooperman and his foundation have reported a 6.3% beneficial ownership stake in DiaMedica Therapeutics Inc., totaling 3,269,761 common shares.

Summary

• Leon G. Cooperman, along with The Leon and Toby Cooperman Foundation, has reported beneficial ownership of 3,269,761 Voting Common Shares of DiaMedica Therapeutics Inc.
• This ownership represents approximately 6.3% of the total outstanding Common Shares of DiaMedica Therapeutics Inc.
• The shares are comprised of 2,450,000 shares held directly by Mr. Cooperman and 819,761 shares held by the Foundation.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, except for activities related to nominations under Rule 14a-11.
• The percentage is calculated based on 51,688,913 Common Shares outstanding as of August 8, 2025, as reported in the Issuer's Form 10-Q filed on August 12, 2025.

Sentiment

Score: 7

Explanation: The disclosure of a 6.3% beneficial ownership by Leon G. Cooperman, a respected investor, and his foundation, is generally perceived as a positive signal, suggesting confidence in DiaMedica Therapeutics Inc.'s long-term value. While the filing is purely factual, the identity of the investor adds a layer of positive sentiment.

Positives

• A prominent investor, Leon G. Cooperman, has disclosed a significant 6.3% stake in DiaMedica Therapeutics Inc., which can be interpreted as a vote of confidence in the company's future prospects.
• The substantial ownership by Mr. Cooperman and his foundation suggests a long-term investment horizon and potential belief in the company's underlying value.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a notable investor like Leon G. Cooperman could instill greater confidence among existing shareholders and potentially attract new investors, positively influencing stock perception.

Key Dates

Recommendation

The disclosure of a significant stake by a prominent investor like Leon G. Cooperman is generally a positive indicator, suggesting confidence in the company's prospects. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial data to warrant an immediate 'buy' or 'strong buy' recommendation without further fundamental analysis. It serves as a signal that warrants continued monitoring and holding existing positions, as the investor's conviction might reflect underlying value not yet fully recognized by the market. A 'hold' recommendation is appropriate as it acknowledges the positive signal without overstating its immediate impact on the company's fundamentals.

Keywords

DiaMedica Therapeutics, DMAC, Leon G. Cooperman, beneficial ownership, Schedule 13G, institutional investor, biotechnology, pharmaceuticals, common shares